April 4, 2025 10:35 AM EDTUpdated 11:19 AM
R&D

Se­cre­tive Chi­nese start­up be­gins first-ever clin­i­cal tri­al of cir­cu­lar RNA ther­a­py

Ryan Cross

Senior Science Correspondent

A Shang­hai-based start­up qui­et­ly be­came the first in the world to start a clin­i­cal tri­al for a cir­cu­lar RNA ther­a­py, a cut­ting-edge form of ge­net­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Bris­tol My­ers CEO sig­nals deal­mak­ing will be a top pri­or­i­ty in 2025

Drug­mak­ers see a sub­stan­tial, but man­age­able, hit to busi­ness from tar­iffs. But the worst may lie ahead

Roche CEO warns that tar­iffs could im­pact deal­mak­ing

Ver­san­t's lat­est biotech fo­cus­es on in­flam­ma­to­ry dis­eases

Roche takes steps to pro­tect it­self from tar­iffs, while Sanofi hangs back

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times